Wednesday, July 8, 2026

pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics NV clinical programs — 62 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
Status
Public
HQ
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
Founded
2016
Employees
9
Programs
99
Drugs
26
Patents
0
Intelligence · Clinical Programs

Lakefront Biotherapeutics NV projects

62 ClinicalTrials.gov programs sponsored by Lakefront Biotherapeutics NV.

Lakefront Biotherapeutics NV has 62 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. GLPG3667

    Lakefront Biotherapeutics NV

    Plaque Psoriasis

    phase 1 small molecule completed

    1 trial
  2. GLPG3667 capsule

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  3. GLPG3667 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  4. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  5. GLPG3970 film-coated tablet

    Lakefront Biotherapeutics NV

    Systemic Lupus Erythematosus

    phase 1 small molecule terminated

    1 trial
  6. GLPG3970 oral solution

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    2 trials
  7. GLPG4059 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial
  8. GLPG4399 oral suspension

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  9. GLPG4716

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  10. MOR106

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule terminated

    1 trial
  11. MOR106 single ascending doses, intravenous

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  12. Pirfenidone

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  13. Sulfasalazine

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial
  14. placebo

    Lakefront Biotherapeutics NV

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Lakefront Biotherapeutics NV have?

62 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.